| HOME >> MEDICINE >> TECHNOLOGY |
SAN JOSE, Calif., Jan. 5 /PRNewswire/ -- Women undergoing in vitro fertilization (IVF) require progesterone medication to help support early pregnancy, but the intramuscular injections for some forms of this medication can be painful for patients. Formulations of progesterone medication which can be administered by subcutaneous injection or vaginal suppository may offer similar results with better patient tolerance.
With patient well-being a constant focus, Fertility Physicians is participating in an international research study to compare an experimental progesterone, Progesterone-IBSA, which is given by subcutaneous injection, to an FDA approved progesterone, Endometrin(R), which is administered vaginally. The study will assess the efficacy, tolerability and safety of Progesterone-IBSA, the study medication, in female patients undergoing IVF.
"We are so pleased to be one of only 8 clinics across the nation asked to participate. The outcome of this study could mean improved comfort and cost for patients undergoing fertility treatment." said Dr. Purcell.
Patients choosing to participate will benefit by receiving progesterone medication (Endometrin(R) or Progesterone-IBSA) for one IVF cycle, at no charge. This represents approximately a $1,036 value. Additionally, $1,500 will be given to each study participant for their time and commitment. Patients will be responsible for all other charges relating to their IVF cycle and treatment.
Enrollment for this research study is now open and patients interested in participating are invited to call the research department at Fertility Physicians for further information on the study.
Dr. Karen Purcell, MD, PhD, FACOG is directing this study at Fertility
Physicians of Northern California, along with Angie Toyama, clinical research
coordinator. This research study is sponsored by Institut Biochimique SA
(IBSA), an establish
'/>"/>
| SOURCE Fertility Physicians of Copyright©2009 PR Newswire. All rights reserved |